The purpose of this study is to determine the need for a blood transfusion during surgery and to evaluate the levels of certain proteins in the blood when given tranexamic acid.
A review of the medical record between January 01 2013 to July 1st 2015 will be used to determine if the hypothesis that patients receiving tranexamic acid will have a lower need for blood transfusion and there are changes in the levels of the proteins essential for healthy oxygen transport throughout the body is correct. Tranexamic acid is a medication which may help wounds to stop bleeding more quickly. Participants are not expected to receive any direct benefits from participating in this study. Only a small risk of private patient medical information being exposed is anticipated. The results of this study will help surgeons and the medical community to better understand the uses of this type of drug and its possible role in benefiting hip replacement patients during and following surgery.
Study Type
OBSERVATIONAL
Enrollment
576
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
hemoglobin, hematocrit, and red blood cell transfusion rates
Whether intraoperative dose of 2gr tranexamic acid (TXA) in patients having primary or revision THA would decrease the perioperative and post-operative reduction in hemoglobin, hematocrit, and red blood cell transfusion rates compared with those of a similar group of patients who did not receive TXA (control group).
Time frame: Peri-operative care
clinically-significant venous thromboembolism (VTE) and all-cause mortality
frequency of clinically-significant venous thromboembolism (VTE) and all-cause mortality within 30 days of surgery
Time frame: within 30 days of surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.